Case Study: Leading Pharmaceutical Company achieves up to 75% faster actinic keratosis enrollment and reduced study spending with IQVIA

Exceeded Enrollment Goal Timelines and Reduced Study Spending

Leading Pharmaceutical Company engaged IQVIA to support several large Phase III actinic keratosis (AK) trials after site enrollment shortfalls threatened program timelines and costs. The sponsor selected IQVIA Biotech for its patient recruitment services and recruitment management (RM) capabilities, including predictive enrollment, to accelerate enrollment without compromising data quality.

IQVIA implemented targeted recruitment campaigns, ongoing media and screening performance analysis, and predictive enrollment forecasting; as a result enrollment completed 15–75% faster than sponsor projections (e.g., Study 1: 6 vs. 16 weeks; Study 3: 3 vs. 12 weeks), actual enrollments met or exceeded targets, RM contributed 33–69% of enrollments, and RM rates per site/week were 33–123% higher—enabling earlier campaign shutdowns, reduced media spend and lower overall study costs.